Topics covered: Uncertainty Around Health Care Reform, Pipeline Product Acquisition Through Corporate Mergers, Investment Ramifications of Biosimilars, Blockbuster Lineup of Patent Cliffs
Companies covered: Teva Pharmaceutical Industries Limited (NYSE:TEVA), Perrigo Company (NYSE:PRGO), Morgan Stanley (NYSE:MS), Johnson & Johnson (NYSE:JNJ), Genzyme Corp., Forest Laboratories Inc., Endo International plc (NASDAQ:ENDP), Abbott Laboratories (NYSE:ABT), Sequenom, Inc. (NASDAQ:SQNM), Myriad Genetics, Inc. (NASDAQ:MYGN), Luminex Corporation (NASDAQ:LMNX), Laboratory Corporation of America Holdings (NYSE:LH), Genomic Health, Inc. (NASDAQ:GHDX), Quest Diagnostics Incorporated (NYSE:DGX), Celgene Corporation (NASDAQ:CELG), Seattle Genetics, Inc. (NASDAQ:SGEN), Pharmacyclics, Inc. (NASDAQ:PCYC), Eli Lilly and Company (NYSE:LLY), Bristol-Myers Squibb Company (NYSE:BMY), Watson Pharmaceuticals Inc., Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), Impax Laboratories, Inc. (NASDAQ:IPXL), PEPCO Holdings, Inc. (NYSE:POM), Adventrx Pharmaceuticals Inc., Pozen, Inc. (NASDAQ:POZN), Apricus Biosciences, Inc (NASDAQ:APRI), Enzo Biochem, Inc. (NYSE:ENZ), Cardiovascular Systems, Inc. (NASDAQ:CSII), Harvard Bioscience, Inc. (NASDAQ:HBIO)
